Company profile
Elicio Therapeutics, Inc.
NASDAQ:ELTXBiotechnology: Pharmaceutical Preparations
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05726864 | phase1_2 | active_not_recruiting | 2023-04-14 | 2026-04-20 | Elicio Therapeutics | A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors |
| NCT04853017 | phase1 | completed | 2021-10-04 | 2023-01-26 | Elicio Therapeutics | A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors |
FDA applications (0)
No records yet.